Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23835, expectations were $-0.28. Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc. (ACRS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 3,282,982 | $4,070,898 | +70% | 0% |
| 2. | Millennium Management Israel Englander | 3,273,492 | $4,059,130 | -6% | 0% |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 2,753,495 | $3,414,334 | -9% | 0.08% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 1,451,100 | $1,799,364 | +3% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 930,003 | $1,153,203 | -83% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.15 | 123,017 | 13,447,969 | 2024-07-05 | Filing | ||
| $1.16 | 143,288 | 13,324,952 | 2024-07-03 | Filing | ||
| $1.14 | 86,092 | 13,181,664 | 2024-07-02 | Filing | ||
| $1.14 | 107,434 | 13,095,572 | 2024-07-01 | Filing | ||
| $1.13 | 400,000 | 12,988,134 | 2024-06-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.08 | 6,000 | Officer | 129,724 | 2023-10-23 | Filing | |
| $7.32 | 6,000 | Officer | 135,724 | 2023-08-21 | Filing | |
| $10.28 | 6,000 | Officer | 141,724 | 2023-06-20 | Filing | |
| $12.63 | 30,240 | Director | 1,273,202 | 2023-03-03 | Filing | |
| $12.37 | 29,000 | Director | 1,285,188 | 2023-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,905,872 | $6,201,167 | 0% | |
| 2. | 4,722,357 | $4,958,476 | 0% | |
| 3. | 3,500,000 | $3,675,000 | 0.35% | |
| 4. | 1,679,905 | $1,763,900 | 0% | |
| 5. | 1,463,461 | $1,536,634 | 0% |
News See All
5 Cheap Small-Cap Stocks to Buy Before the Next Breakout
In this piece, we will take a look at five cheap small cap stocks to buy before the next breakout.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to Aclaris Therapeutics First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.
Did Hedge Funds Catch A Break With Aclaris Therapeutics, Inc. (ACRS)?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Is Aclaris Therapeutics, Inc. (ACRS) Going to Burn These Hedge Funds?
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...
5 Best Healthcare Stocks to Buy According to Greg Martinez's Parkman Healthcare Partners
In this article, we discuss the 5 best healthcare stocks to buy according to Greg Martinez's Parkman Healthcare Partners.
Hedge Funds Are Crazy About Aclaris Therapeutics, Inc. (ACRS)
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
15 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs' Samsara BioCapital
In this article, we will discuss 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs' Samsara BioCapital.
5 Best Small-Cap Stocks to Buy According to Hedge Funds
In this article, we discuss the 5 best small-cap stocks to buy according to hedge funds.
10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman
In this article, we will discuss the 10 best pharmaceutical stocks to buy according to billionaire Joseph Edelman.
Billionaire Hedge Funds
